Knut Eis

USPTO Granted Patents = 41 (Patent Applications = 14)

CIPO Patents = 1 (Patent Applications = 12)

EPO Patents = 20 (Patent Applications = 36)

Average Co-Inventor Count = 11.3

ph-index = 7

Forward Citations = 161(Granted Patents)

Location History:

Leverkusen, DE (2022)
Berlin, DE (2009 - 2024)

Company Filing History:

26 out of 378

Bayer Pharma Aktiengesellschaft

patents

12 out of 443

The Broad Institute, Inc.

patents

11 out of 721

Bayer Intellectual Property Gmbh

patents

4. 9 out of 12,157

Bayer Aktiengesellschaft

The General Hospital Corporation

patents

7. 4 out of 192

Bayer Schering Pharma Ag

patents

8. 4 out of 1,206

Dana-farber-cancer Institute Inc.

patents

9. 1 out of 1,384

Schering Aktiengesellschaft

patents

10. 1 out of 1

Bayer Pharma Aktiengellschaft

patent

11. 1 out of 5

Bayer Aktiengellschaft

patents

12. 1 out of 1

Bayer Pharma Aktiegellschaft

patent

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

41 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12486248 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2025-12-02),

2. 12053476 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2024-08-06),

3. 11787797 - 4,5-annulated 1,2,4-triazolones (2023-10-17),

4. 11713304 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2023-08-01),

5. 11529356 - 2-(morpholin-4-yl)-1,7-naphthyridines (2022-12-20),

6. 11492358 - Macrocyclic indole derivatives (2022-11-08),

7. 11339157 - 4H-pyrrolo[3,2-c]pyridin-4-one derivatives (2022-05-24),

8. 11142522 - Compounds, compositions and methods for cancer treatment (2021-10-12),

9. 11130745 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2021-09-28),

10. 10981932 - Macrocyclic indole derivatives (2021-04-20),

11. 10968216 - 4,5-annulated 1,2,4-triazolones (2021-04-06),

12. 10966986 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2021-04-06),

13. 10894784 - Heteroarylbenzimidazole compounds (2021-01-19),

14. 10815215 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2020-10-27),

15. 10772893 - 2-(morpholin-4-yl)-1,7-naphthyridines (2020-09-15),

Title: Knut Eis: Pioneering Inventor from Berlin

Introduction: Knut Eis is a renowned inventor hailing from the vibrant city of Berlin, Germany. With a passion for innovation and a keen eye for problem-solving, he has made significant contributions to various fields through his groundbreaking inventions.

Latest Patents: Knut Eis holds several patents in the areas of renewable energy technologies, sustainable transportation solutions, and advanced materials science. His most recent patents focus on enhancing the efficiency of solar panels and developing eco-friendly alternatives to traditional plastics.

Career Highlights: Throughout his illustrious career, Knut Eis has worked with leading research institutions and technology companies to bring his inventions to life. His innovative spirit and dedication to creating a more sustainable future have earned him recognition as a trailblazer in the field of clean technology.

Collaborations: Knut Eis has collaborated with top engineers, scientists, and designers to push the boundaries of what is possible in the world of innovation. His partnerships with industry experts have led to the development of cutting-edge products that have the potential to revolutionize the way we live and work.

Conclusion: In conclusion, Knut Eis stands as a visionary inventor whose work continues to inspire and shape the future of technology. His relentless pursuit of excellence and commitment to sustainability make him a true pioneer in the world of invention.

This text is generated by artificial intelligence and may not be accurate.